The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Axsome Therapeutics Inc shares valued at $5,241,127 were sold by Jacobson Mark L. on Sep 16 ’25. At $114.48 per share, Jacobson Mark L. sold 45,783 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
Also, TABUTEAU HERRIOT sold 27,907 shares, netting a total of over 3,319,817 in proceeds. Following the sale of shares at $118.96 each, the insider now holds 7,229 shares.
Before that, TABUTEAU HERRIOT had sold 19,719 shares from its account. In a trade valued at $2,251,713, the Chief Executive Officer traded Axsome Therapeutics Inc shares for $114.19 each. Upon closing the transaction, the insider’s holdings decreased to 19,719 shares, worth approximately $0.84 million.
As of June 03, 2025, Oppenheimer has initiated its “an Outperform” rating for AXSM. Earlier on April 07, 2025, Jefferies initiated its rating. Their recommendation was “a Buy” for AXSM stock.
Analyzing AXSM Stock Performance
On last trading session, Axsome Therapeutics Inc [NASDAQ: AXSM] rose 2.21% to $116.62. The stock’s lowest price that day was $113.85, but it reached a high of $118.432 in the same session. During the last five days, there has been a drop of approximately -6.04%. Over the course of the year, Axsome Therapeutics Inc shares have jumped approximately 24.50%.
Is Axsome Therapeutics Inc subject to short interest?
Stocks of Axsome Therapeutics Inc saw a sharp steep in short interest on 2025-08-29 dropping by -0.16 million shares to 3.51 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 3.67 million shares. A decline of -4.68% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.0 of the overall float, the days-to-cover ratio (short ratio) decline to 6.0.
Which companies own the most shares of Axsome Therapeutics Inc (AXSM)?
In terms of Axsome Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 163 in the next 12 months, up nearly 42.86% from the previous closing price of $114.1. Analysts anticipate Axsome Therapeutics Inc stock to reach 216 by 2025, with the lowest price target being 162. In spite of this, 15 analysts ranked Axsome Therapeutics Inc stock as Buy at the end of 2025. On February 11, 2025, Deutsche Bank assigned a price target of “a Buy” to the stock and initiated coverage with a $176.
